Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It [0.03%]
非肌层浸润性膀胱癌：许多患者是死于该病而非因该病去世
Kathryn McGonagle,Ellen J Dematt,Zhibao Mi et al.
Kathryn McGonagle et al.
Background: The National Cancer Institute SEER Program regularly publishes bladder-cancer specific survival statistics. However, this data is for all bladder cancers, and information for non-muscle invasive bladder cancer...
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis [0.03%]
新辅助顺铂、吉西他滨和多西他赛治疗梭形细胞膀胱癌：临床活性及全转录组分析
Burles A Johnson Iii,Benjamin A Teply,Catherine Kagemann et al.
Burles A Johnson Iii et al.
Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. Objec...
Edward M Messing
Edward M Messing
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward [0.03%]
那多法拉基因非达诺韦克的发展历程：综述与展望路径
Alexis R Steinmetz,Sharada Mokkapati,David McConkey et al.
Alexis R Steinmetz et al.
Background: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene ...
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival [0.03%]
根治性膀胱前列腺切除标本中的意外发现前列腺癌与总体生存率降低有关
Takahiro Kimura,Hajime Onuma,Shun Sato et al.
Takahiro Kimura et al.
Background: The impact of incidental prostate cancer (IPC) on oncological outcomes after radical cystoprostatectomy (RCP) specimens from patients with bladder cancer (BC) remains controversial. This relationship has not b...
Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma [0.03%]
TaG1G2期尿路上皮膀胱癌患者术后单次膀胱灌注化疗严重并发症发生率低
Lisa M C van Hoogstraten,J Alfred Witjes,Theodora M Ripping et al.
Lisa M C van Hoogstraten et al.
Background: EAU guidelines recommend a single instillation (SI) of intravesical chemotherapy (e.g. Mitomycin C) within 24 hours after transurethral resection of a bladder tumour (TURBT) in patients with low- to intermedia...
Piyush K Agarwal,Cora N Sternberg
Piyush K Agarwal
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study [0.03%]
肌肉侵袭性膀胱癌的血栓栓塞：基于全国人口的队列研究
Staffan Jahnson,Truls Gårdmark,Abolfazl Hosseini et al.
Staffan Jahnson et al.
Background: Routine VTE prophylaxis within 30 days of radical cystectomy (RC) for urinary bladder cancer (UBC) is used to protect from venous thromboembolism (VTE). However, randomized studies and nationwide population-ba...
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection [0.03%]
系统评价：非肌层浸润性膀胱癌经尿道切除术（TURBT）后辅助或预防治疗的有效性试验的结局报告、定义及测量异质性
Erik Veskimae,Selvarani Subbarayan,Riccardo Campi et al.
Erik Veskimae et al.
Background: Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hi...
Significance and Mechanisms Analyses of RB1 Mutation in Bladder Cancer Disease Progression and Drug Selection by Bioinformatics Analysis [0.03%]
生物信息学分析RB1基因突变在膀胱癌疾病进展和药物选择中的意义及机制分析
Dingguo Zhang,Jinjun Tian,Qier Xia et al.
Dingguo Zhang et al.
Background: Bladder cancer is still a disease of significant morbidity and mortality. In bladder cancer, RB1 is one of the most common mutant genes. Metho...